All News

steroids.prednisone.pills_.jpg

Mortality in Low Dose Prednisone

Eric Dein, MD

Upon release of the new ACR 2020 Pharmacologic Treatment Recommendations for the Management of Rheumatoid Arthritis, many practitioners were surprised that the new guidelines recommended against glucocorticoid initiation at disease onset.

Read Article
podcast logo

RheumNow Podcast – Back Talk Listener Questions (12.04.20)

Jack Cush, MD

Dr Jack Cush takes questions from RheumNow listeners

Read Article
pregnant-776506__180.jpg

PIANO Study - Safety of Biologics in Pregnancy

Jack Cush, MD

The results of the long awaited PIANO study have been reported in the journal Gastroenterology, showing that pregnant women with IBD may safely receive biologic or thiopurine therapy throughout the pregnancy without substantial added risk to the unborn or mother.

Read Article
cost.healthcare.jpg

Colchicine Approval Took a Huge Toll on CMS

Colchicine, the old gout drug often cited as a cheap anti-inflammatory, hasn't been such a good deal since FDA approval, a study in JAMA Internal Medicine showed.

Read Article
chalkboard disparities black white

Racial disparities in Bilateral Knee Arthroplasty in Osteoarthritis

Bella Mehta, MBBS, MS

Although arthritis-related activity, disabling work limitations, and severe pain (which are indications for TKA) disproportionately impact African American patients compared to White patients, there are marked racial disparities documented in utilization and complications in unilateral total knee arthroplasty.  

Read Article
Lknee.OA_.jpg

What’s new in knee osteoarthritis that matters?

Janet Pope, MD, MPH, FRCPC

Are intra-articular steroid injections effective in symptomatic knee OA? Do they accelerate cartilage loss? Does weight less actually help? Do we have DMARDs for knee OA? Insights from 2020 ACR Convergence.

Read Article
podcast logo

RheumNow Podcast – ACR 2020 Epilogue (11.20.20)

Jack Cush, MD

Dr. Jack Cush reviews a few more ACR 2020 abstracts and presents a new plan to learn or take in ACR20 content.

Read Article
covid19.logo_.jpg

COVID and Rheumatic Disease Patients: Dr. Kevin Winthrop

Kevin Winthrop, MD, MPH

Portland-based Dr. Kevin Winthrop from OHSU discusses Saturday ACR 2020 posters #0623 and #0629 related to COVID-19 and rheumatic disease patients.

Read Article
#BestACR20Tweets RT @ejdein1 : Draft #ACR20 Rx Recommendations for RA: MTX monotherapy conditionally rec over csDMARD dual or triple Rx, MTX+TNFi @RheumNow https://t.co/HUucJOgQgN https://t.co/xJB2zU1y2U

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @ejdein1 : Draft #ACR20 Rx Recs for RA: on max tolerated MTX - add bio or tsDMARD conditional recommendation over triple therapy (MTX, HCQ, SSZ). @RheumNow. https://t.co/uff7Vj0iKA https://t.co/Tquq7FN86y

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @MeralElRamahiMD : Switching or adding a DMARD in pts w/ mod-high dz RA activity ; hx of previous serious infection w/in the past 12 mos as opposed to starting/increasing GCs is conditionally recommended per draft recs of new ACR RA treatment guidelines.

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @KDAO2011 : Very strong push by #ACR20 to recc MTX in most RA patient scenarios including RA ILD, RA nodules, NAFLD in new RA guidance document @rheumnow

Dr. John Cush RheumNow ( View Tweet)

Dr. Janet Pope ( @Janetbirdope) reviews abstract #1001 presented at #ACR20 on risk of skin cancer with methotrexate. https://t.co/N0JelI6K5p https://t.co/n07HoO5j3y

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @ejdein1:Abst#2001: Heme changes on MTX? CIRT trial (non-rheumatic pts): Low-dose MTX (15-20mg/w): 2 line cytopenia uncommon (4%), pancytopenia rare (0.5%), Hb decrease 0.4 g/dL but WBC, plt unchanged. Reassuring large pop study shows tolerance of MTX #ACR20

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @ejdein1 :Abst#2001: Heme changes on MTX? CIRT trial (non-rheumatic pts): Low-dose MTX (15-20mg/w):2 line cytopenia uncommon (4%), pancytopenia rare (0.5%), Hb decrease 0.4 g/dL but WBC, plt unchanged. Reassuring large pop study shows tolerance of MTX #ACR20

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @MeralElRamahiMD : When do you think we are going to get a DMARD for OA? 50% or more over age 60 will have osteoarthritis, yet we are yet to discover a promising disease modifying therapy. #ACR20 @ElaineHusniMD

Dr. John Cush RheumNow ( View Tweet)

What is the SEAMless transition from combination Etanercept to Methotrexate? with Dr. Jonathan Kay #ACR20 https://t.co/58raeaE8Mr https://t.co/FUIidcoy4I

Links:

Dr. John Cush RheumNow ( View Tweet)
SEAM-RA Trial: Dr. Jeff Curtis ( @RADoctor) discusses abstract # 0939 that looked at whether RA patients at or close to remission should continue taking their combination therapy, as presented at #ACR20 https://t.co/2yMyj4BKs1 https://t.co/2gqJM4EKpG

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. David Liew ( @drdavidliew) reviews abstracts #0431 on HCQ and QTc Prolongation as presented at #ACR20. https://t.co/vbqf7UNzVY https://t.co/qBCqFqYQCo

Links:

Dr. John Cush RheumNow ( View Tweet)
Methotrexate Induced Liver Fibrosis: Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract #0205 presented Friday at the #ACR20 annual meeting. https://t.co/P80WIGXOPg https://t.co/xEAuxSqIQv

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×